Logo image of BLRX

BIOLINERX LTD-SPONS ADR (BLRX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BLRX - US09071M2052 - ADR

2.88 USD
0 (0%)
Last: 1/16/2026, 8:00:01 PM
2.89 USD
+0.01 (+0.35%)
After Hours: 1/16/2026, 8:00:01 PM
Fundamental Rating

1

Taking everything into account, BLRX scores 1 out of 10 in our fundamental rating. BLRX was compared to 525 industry peers in the Biotechnology industry. Both the profitability and financial health of BLRX have multiple concerns. BLRX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • BLRX had negative earnings in the past year.
  • In the past year BLRX has reported a negative cash flow from operations.
  • In the past 5 years BLRX always reported negative net income.
  • In the past 5 years BLRX always reported negative operating cash flow.
BLRX Yearly Net Income VS EBIT VS OCF VS FCFBLRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • The Return On Assets of BLRX (-7.48%) is better than 85.52% of its industry peers.
  • BLRX has a Return On Equity of -15.24%. This is amongst the best in the industry. BLRX outperforms 85.52% of its industry peers.
Industry RankSector Rank
ROA -7.48%
ROE -15.24%
ROIC N/A
ROA(3y)-50.4%
ROA(5y)-49.58%
ROE(3y)-191.99%
ROE(5y)-150.4%
ROIC(3y)N/A
ROIC(5y)N/A
BLRX Yearly ROA, ROE, ROICBLRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

  • BLRX has a Gross Margin of 50.69%. This is in the better half of the industry: BLRX outperforms 76.00% of its industry peers.
  • The Profit Margin and Operating Margin are not available for BLRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 50.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BLRX Yearly Profit, Operating, Gross MarginsBLRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

2

2. Health

2.1 Basic Checks

  • BLRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, BLRX has more shares outstanding
  • Compared to 5 years ago, BLRX has more shares outstanding
  • BLRX has a worse debt/assets ratio than last year.
BLRX Yearly Shares OutstandingBLRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
BLRX Yearly Total Debt VS Total AssetsBLRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • BLRX has an Altman-Z score of -13.13. This is a bad value and indicates that BLRX is not financially healthy and even has some risk of bankruptcy.
  • BLRX's Altman-Z score of -13.13 is on the low side compared to the rest of the industry. BLRX is outperformed by 77.33% of its industry peers.
  • A Debt/Equity ratio of 0.34 indicates that BLRX is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.34, BLRX is not doing good in the industry: 68.38% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Altman-Z -13.13
ROIC/WACCN/A
WACC38.76%
BLRX Yearly LT Debt VS Equity VS FCFBLRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

  • BLRX has a Current Ratio of 2.09. This indicates that BLRX is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 2.09, BLRX is not doing good in the industry: 75.24% of the companies in the same industry are doing better.
  • BLRX has a Quick Ratio of 1.93. This is a normal value and indicates that BLRX is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.93, BLRX is doing worse than 75.05% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.09
Quick Ratio 1.93
BLRX Yearly Current Assets VS Current LiabilitesBLRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

0

3. Growth

3.1 Past

  • BLRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 87.78%, which is quite impressive.
  • Looking at the last year, BLRX shows a very negative growth in Revenue. The Revenue has decreased by -42.09% in the last year.
EPS 1Y (TTM)87.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.84%
Revenue 1Y (TTM)-42.09%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-91.36%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BLRX Yearly Revenue VS EstimatesBLRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 5M 10M 15M 20M 25M
BLRX Yearly EPS VS EstimatesBLRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 -50 -100 -150 -200

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • BLRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BLRX Price Earnings VS Forward Price EarningsBLRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BLRX Per share dataBLRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • BLRX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

BIOLINERX LTD-SPONS ADR

NASDAQ:BLRX (1/16/2026, 8:00:01 PM)

After market: 2.89 +0.01 (+0.35%)

2.88

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-24
Earnings (Next)03-19
Inst Owners0%
Inst Owner Change0%
Ins Owners0.16%
Ins Owner ChangeN/A
Market Cap10.72M
Revenue(TTM)12.73M
Net Income(TTM)-2.98M
Analysts100
Price TargetN/A
Short Float %4.8%
Short Ratio6.59
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.84
P/FCF N/A
P/OCF N/A
P/B 0.55
P/tB 1.17
EV/EBITDA N/A
EPS(TTM)-1.54
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-3.62
FCFYN/A
OCF(TTM)-3.62
OCFYN/A
SpS3.42
BVpS5.25
TBVpS2.46
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7.48%
ROE -15.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 50.69%
FCFM N/A
ROA(3y)-50.4%
ROA(5y)-49.58%
ROE(3y)-191.99%
ROE(5y)-150.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.09
Quick Ratio 1.93
Altman-Z -13.13
F-Score3
WACC38.76%
ROIC/WACCN/A
Cap/Depr(3y)23.7%
Cap/Depr(5y)16.98%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)87.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.84%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-42.09%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-91.36%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y62.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y60.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y59.49%
OCF growth 3YN/A
OCF growth 5YN/A

BIOLINERX LTD-SPONS ADR / BLRX FAQ

Can you provide the ChartMill fundamental rating for BIOLINERX LTD-SPONS ADR?

ChartMill assigns a fundamental rating of 1 / 10 to BLRX.


Can you provide the valuation status for BIOLINERX LTD-SPONS ADR?

ChartMill assigns a valuation rating of 0 / 10 to BIOLINERX LTD-SPONS ADR (BLRX). This can be considered as Overvalued.


What is the profitability of BLRX stock?

BIOLINERX LTD-SPONS ADR (BLRX) has a profitability rating of 2 / 10.


How financially healthy is BIOLINERX LTD-SPONS ADR?

The financial health rating of BIOLINERX LTD-SPONS ADR (BLRX) is 2 / 10.